Search

Stephen G Zegarelli

from Syracuse, NY
Age ~65
Get Report
Also known as:
Steve G Zegarelli
Phone and address:
108 Wilshirl Dr, Syracuse, NY 13212
(315) 458-0898
Related to:
Joanne H Maurice, 69Mary C DevlinChristopher A Zegarelli, 42Pamela Devlin, 66Louise M ZegarelliKeith A Devlin, 64Holly V Zegarelli, 39Michael J Allen, 46Allen C Babcock, 55Donna M Devlin, 65L E Devlin
Connected to:
Martin R Zegarelli, 94Nicholas J Zegarelli, 42Rana Zegarelli, 53Eric A Zegarra, 47Felipe A Zegarra, 29Gonzalo Zegarra, 39Kelly E Zegarra, 45Liliana Zegarra, 68Lucy H Zegarra, 70Marcos J Zegarra, 59

Stephen Zegarelli Phones & Addresses

  • 108 Wilshirl Dr, Syracuse, NY 13212 (315) 458-0898 (607) 458-0898
  • North Syracuse, NY
  • Utica, NY
  • East Syracuse, NY
  • 108 Wilshirl Dr, North Syracuse, NY 13212 (315) 458-0898

Work

Company: Bristol-myers squibb Sep 1990 Position: Senior technologist

Education

Degree: Bachelors, Bachelor of Arts School / High School: Le Moyne College 1999 to 2009 Specialities: Biology

Skills

Biopharmaceuticals • Gmp • Validation • Pharmaceutical Industry • Sop • Chromatography • Technology Transfer • Lims • Fda • Glp • Life Sciences • Capa

Emails

z***[email protected]

Industries

Pharmaceuticals

Resumes

Resumes

Stephen Zegarelli Photo 1

Senior Technologist

View page
Location:
105 Decker Ct, Irving, TX 75062
Industry:
Pharmaceuticals
Work:
Bristol-Myers Squibb
Senior Technologist
Education:
Le Moyne College 1999 - 2009
Bachelors, Bachelor of Arts, Biology
Skills:
Biopharmaceuticals
Gmp
Validation
Pharmaceutical Industry
Sop
Chromatography
Technology Transfer
Lims
Fda
Glp
Life Sciences
Capa

Publications

Us Patents

Mammalian Cell Culture Processes For Protein Production

View page
US Patent:
7541164, Jun 2, 2009
Filed:
Dec 18, 2003
Appl. No.:
10/742564
Inventors:
Bernhard M. Schilling - Syracuse NY, US
Linda Matlock - Parish NY, US
Stephen G. Zegarelli - North Syracuse NY, US
William V. Burnett - Fayetteville NY, US
Christoph E. Joosten - Manlius NY, US
Jonathan D. Basch - East Syracuse NY, US
Sivakesava Sakhamuri - Syracuse NY, US
Steven S. Lee - Manlius NY, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C12N 5/06
A61K 39/395
A61K 38/00
US Classification:
435 701, 435 41, 4241431, 4241851, 53038822, 5303873
Abstract:
The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. Throughout their duration, the culturing processes of the invention involving two or more downward shifts in temperature sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e. g. , by sialic acid content of the produced protein. In another aspect, the methods comprise the delayed addition of polyanionic compound during the culturing period.

Product Quality Enhancement In Mammalian Cell Culture Processes For Protein Production

View page
US Patent:
20050084933, Apr 21, 2005
Filed:
Dec 18, 2003
Appl. No.:
10/740645
Inventors:
Bernhard Schilling - Syracuse NY, US
Scott Gangloff - Bensalem PA, US
Dharti Kothari - Princeton NJ, US
Kirk Leister - Fayetteville NY, US
Linda Matlock - Parish NY, US
Stephen Zegarelli - North Syracuse NY, US
Christoph Joosten - Manlius NY, US
Jonathan Basch - Dewitt NY, US
Sivakesava Sakhamuri - Manlius NY, US
Steven S. Lee - Manlius NY, US
International Classification:
C12P021/02
C12N005/06
US Classification:
435069100, 435358000, 435404000
Abstract:
The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after innoculation. Supplementation of the cultures with D-galactose, preferably in a feed medium, to sustain galactose at sialylation effective levels in the cultures until the end of a culture run reverses a decline in sialylation that accompanies culture scale up, and is advantageous for large scale culturing processes.

Product Quality Enhancement In Mammalian Cell Culture Processes For Protein Production

View page
US Patent:
20080070280, Mar 20, 2008
Filed:
Oct 22, 2007
Appl. No.:
11/975799
Inventors:
Bernhard Schilling - Syracuse NY, US
Scott Gangloff - Langhorne PA, US
Dharti Kothari - Princeton NJ, US
Kirk Leister - Fayetteville NY, US
Linda Matlock - Parish NY, US
Stephen Zegarelli - North Syracuse NY, US
Christoph Joosten - Manlius NY, US
Jonathan Basch - Dewitt NY, US
Sivakesava Sakhamuri - Manlius NY, US
Steven Lee - Manlius NY, US
International Classification:
C12P 21/04
US Classification:
435071100
Abstract:
The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after inoculation. Supplementation of the cultures with D-galactose, preferably in a feed medium, to sustain galactose at sialylation effective levels in the cultures until the end of a culture run reverses a decline in sialylation that accompanies culture scale up, and is advantageous for large scale culturing processes.

Mammallian Cell Culture Process For Protein Production

View page
US Patent:
20120015438, Jan 19, 2012
Filed:
Mar 18, 2009
Appl. No.:
12/381938
Inventors:
Bernhard M. Schilling - Syracuse NY, US
Linda Matlock - Parish NY, US
Stephen G. Zegarelli - North Syracuse NY, US
William V. Burnett - Fayetteville NY, US
Christoph E. Joosten - Manlius NY, US
Jonathan D. Basch - Dewitt NY, US
Sivakesava Sakhamuri - Manlius NY, US
Steven S. Lee - Manlius NY, US
International Classification:
C12N 5/10
US Classification:
435362, 435325, 435358
Abstract:
The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. Throughout their duration, the culturing processes of the invention involving two or more downward shifts in temperature sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein. In another aspect, the methods comprise the delayed addition of polyanionic compound during the culturing period. The delayed addition of polyanionic compound sustains a high viability of the cultured cells, and can extend the growth phase, delay the onset of the death phase, and arrest the death phase.
Control profile
Stephen G Zegarelli from Syracuse, NY, age ~65 Get Report